As a result of the closing, the company will issue 5.77 million shares of common stock and warrants to acquire 5.77 million shares of common stock at an exercise price of $1.30 per share to the purchasers.
Stanley Stein, president and CEO of Oragenics (Oni BioPharma), said: “We are very pleased that we were able to close this expected financing on a timely basis and obtain the approval from the American stock exchange for the listing of the additional shares. With this financing we are able to continue our commitment to deliver shareholder value through the development and commercialization of our products.”